0744 GMT - Faster price erosion and high rebates by insurers in the U.S. obesity market could overshadow Roche's long-term opportunities there, Morgan Stanley analysts say in a note. The Zealand Pharma deal to co-develop a weight-loss therapy with petrelintide allows the Swiss pharma giant to access a differentiated and current best-in-class obesity treatment and signals a commitment to the segment, they say. Morgan Stanley analysts expect petrelintide peak sales of 7 billion Swiss francs, which could support a consensus upgrade by 4%. Recent share-value increase suggest that the market has already priced in this. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 13, 2025 03:46 ET (07:46 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.